Mary Ann Liebert: Long-Term Survival and Cardiac Efficacy of Gene Therapy for Duchenne Muscular Dystrophy
December 05, 2024
December 05, 2024
NEW ROCHELLE, New York, Dec. 5 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new study published in the peer-reviewed journal Human Gene Therapy evaluated the long-term survival and cardiac efficacy of the gene therapy delandistrogene moxeparvovec in a rat model of Duchenne muscular dystrophy (DMD). Click here (https://www.liebertpub.com/doi/10.1089/hum.2024.013) to read the article now.
Delandistrogene moxeparvovec uses an adeno-associated vira . . .
A new study published in the peer-reviewed journal Human Gene Therapy evaluated the long-term survival and cardiac efficacy of the gene therapy delandistrogene moxeparvovec in a rat model of Duchenne muscular dystrophy (DMD). Click here (https://www.liebertpub.com/doi/10.1089/hum.2024.013) to read the article now.
Delandistrogene moxeparvovec uses an adeno-associated vira . . .